Preclinical testing of drug delivery systems to bone

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Orthopedic Research

Background:

• 5-10% of bone fractures fail to heal, necessitating advanced therapeutic strategies.
• Drug delivery systems, often incorporating scaffolds with bioactive factors or cells, are essential for promoting bone regeneration.
• Pre-clinical evaluation in animal models is a critical step before human application.

Purpose of the Study:

• To outline the considerations for selecting appropriate animal models for testing bone regeneration drug delivery systems.
• To emphasize the importance of aligning model selection with specific research questions (functional vs. mechanistic) and defect types (load-bearing vs. non-load-bearing).
• To highlight the necessity of adhering to the 3R principles (Replacement, Reduction, Refinement) and ARRIVE guidelines for ethical and transparent research.

Main Methods:

• Review of factors influencing animal model selection for bone defect studies.
• Discussion on differentiating between load-bearing and non-load-bearing bone defect models.
• Emphasis on the application of the 3R principles and ARRIVE guidelines in experimental design.

Main Results:

• The choice of animal model is contingent upon the research objective (functional or mechanistic evaluation).
• The type of bone defect (e.g., orthopedic vs. craniomaxillofacial) dictates the appropriate animal model and species.
• Standardized reporting and ethical considerations are paramount for reliable pre-clinical data.

Conclusions:

• Appropriate animal model selection is key for the successful evaluation of drug delivery systems for bone regeneration.
• Adherence to ethical standards and reporting guidelines ensures the validity and reproducibility of pre-clinical bone defect research.
• This framework aids researchers in designing robust studies for enhancing fracture healing.